Available evidence to guide clinicians in the management of psoriasis patients with a history
of malignancies is scarce. The latest generation of biological drugs is traditionally …

Introduction There is a complex interplay between psoriasis and cancer, with therapeutic
implications. Patients with psoriasis have an increased risk of developing several types of …

Background and objectives A new, updated AEDV Psoriasis Group (GPs) consensus
document on the treatment of moderate to severe psoriasis was needed owing to the …

Justificación y objetivos La aprobación de un gran número de nuevos fármacos en los
últimos años y los cambios en el paradigma de tratamiento de la psoriasis hacen …

Abstract Background and Objective Biologics for psoriasis, especially anti-tumor necrosis
factor-α therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …

The treatment of moderate to severe plaque psoriasis in patients with history of malignancy
is challenging. To review the studies reporting the experience with IL‐17A inhibitors in …

Psoriasis is a chronic inflammatory condition for which eleven FDA-approved biologic
therapies are approved. Over the past decade, studies have documented the higher efficacy …

Background Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has
demonstrated an excellent safety and efficacy profile in phase 3 studies. Objective To …

Background Adipose tissue is infiltrated with various immune cells, including Th17
lymphocytes and monocytes/macrophages, in obese individuals. We have previously …

Background Psoriasis is a chronic immune-mediated inflammatory skin disease which can
also involve joints. It is often associated with burdensome comorbidities which negatively …